Dear Doctor,
Radioligand therapy (RLT) is becoming an important pillar of cancer care globally. To meet the need for widespread patient access to this therapy, there is a need to attract younger physicians to this area of medicine. Further, patient access in Switzerland will only be secured through strong multidisciplinary collaboration between oncologists and nuclear medicine physicians keeping up with the rapidly evolving clinical science. The objective of this event is therefore to train and connect young oncologists and nuclear medicine physicians interested in making RLT an essential pillar of oncology treatment.
Come and help us shape the future of cancer care in Switzerland!
We look forward to your attendance.
This year we will be awarding three travel awards to attend the ASCO, ESMO and EANM conferences:
· ASCO 2026, April 29 – May 2, Chicago, USA
· EANM 2025, October 17-21, Vienna, Austria
· ESMO 2026, October 23-27, Madrid, Spain
What can you expect from the award?
Mentorship
Travel, accommodation and registration fees*
*while adhering to 33% co-payment rule as outlined in Swiss Ordinance VITH
You must fulfill at least 2 of the following criteria:
Have a nuclear medicine FMH title
Be an experienced speaker involved in previous events
Have published research in RLT/nuclear medicine
Have been an investigator on clinical trials
Have treated a significant number of patients with RLT
Have been involved in local/international guidelines
Are a board member of a medical society
Apply by April 17th
Send your CV, motivation letter & letter of recommendation to gabriela.fosado_wyhooge@novartis.com. The steering committee will select the winners based on academic standing (i.e. the criteria listed above). Applicants should be in residency or have completed their FMH title in the last 5 yrs from the application deadline. Travel award winners will have the privilege of presenting their highlights of ASCO/ESMO/EANM at this event under the mentorship of Prof Schaefer.
HUG, Geneva
Inselspital, Bern
Onkozentrum, Zürich
CHUV, Lausanne
Bürgerspital Solothurn
USZ, Zürich
Chairs: Drs Omlin & Schaefer
Nucl Med - TBD
Oncologist - TBD
Nucl Med - TBD
Chair: Dr Wissmeyer
3 cases @ 30 min (NM/Onc)
NM & Onco Case 1
NM & Onco Case 2
NM & Onco Case 3
Chairs: Drs Lorch & Garibotto
Dr Burger, KSB/USZ/ETH
Dr Schaefer, CHUV
Novartis Pharma Schweiz AG
Suurstoffi 14
6343 Rotkreuz
Novartis considère que la protection des données personnelles est une question très importante. Par conséquent, Novartis s'efforce de faire preuve de la plus grande transparence dans le traitement des informations personnelles.
Politique de confidentialité | Novartis Suisse
Novartis anerkennt und respektiert die Datenschutzrechte von Einzelpersonen. Um mehr darüber zu erfahren, wie Novartis mit Ihren personenbezogenen Daten umgeht, können Sie die Novartis Datenschutzerklärung unter diesem Link einsehen Datenschutzerklärung | Novartis Schweiz